Every 10-Q that Onconetix, Inc. (ONCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ONCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCO filings page.
Onconetix, Inc. reports very limited commercial traction and ongoing heavy losses while highlighting substantial doubt about its ability to continue as a going concern. For the six months ended June 30, 2026, revenue was only $38,577, while the company recorded a net loss of $7.1 million.
Cash totaled $5.9 million with a working capital surplus of about $3.6 million, but operating activities used $4.0 million of cash in six months. The company also booked $8.6 million of goodwill impairment and has accumulated a deficit of $138.3 million. Management discloses that recent and expected losses, negative operating cash flows, and dependence on external financing create substantial doubt about continuing as a going concern.
Subsequent events include a Series F preferred financing with $30.2 million stated purchase price that generated only $0.25 million of net cash, and a new equity line facility of up to $750 million, tied to a $30 million commitment fee applied toward that preferred purchase.
Onconetix, Inc. reported a first‑quarter 2026 net loss of $4.2 million, narrower than $8.5 million a year earlier, driven largely by non‑cash items. Revenue fell to $21,457 from $101,630, all from Proclarix diagnostics, resulting in a small gross loss.
The company recorded a further goodwill impairment of about $8.1 million, reducing goodwill to $10.2 million. A large favorable change in the fair value of Series D and Series E derivative liabilities added other income of about $6.0 million, partly offsetting operating losses.
Cash was $3.7 million at March 31, 2026, with about $2.1 million used in operating activities during the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern, noting ongoing losses, limited cash and no committed financing.
Capital structure is highly complex, with multiple preferred series, warrants and an equity line of credit. Subsequent to quarter‑end, conversions of Series D and Series E preferred stock and an ELOC draw increased common shares outstanding to 11,464,572 by May 12, 2026, significantly diluting existing holders. Onconetix also signed a Share Exchange Agreement with Realbotix Corp. that could transfer 75–90% of fully diluted equity to Realbotix’s owner, contingent on minimum net cash, an additional equity line and full conversion of its preferred stock.
Onconetix, Inc. reported a wider quarterly loss and reiterated going‑concern risks. Q3 revenue was $303,651 versus $406,859 a year ago, and the net loss was $8,783,702 versus $3,827,405. For the first nine months, revenue totaled $511,775 compared with $1,812,140 last year, with a net loss of $19,702,029.
Cash was $836,556 and working capital deficit about $15.0 million as of September 30, 2025; management disclosed cash of about $6.1 million as of November 10, 2025. The company closed a Series D financing in Q3 and a Series E in October, and settled Veru notes, recognizing a $5.38 million loss on extinguishment of note payable and a $2.54 million loss on issuance of preferred stock and warrants in Q3.
Year‑to‑date, goodwill impairment was $11.5 million, leaving goodwill at $18,180,299. Fair‑value liabilities at quarter‑end included $12,815,000 warrant liabilities and $988,000 derivative liabilities. Management states there is substantial doubt about the ability to continue as a going concern despite recent financings.
Onconetix, a commercial-stage biotech that acquired Proteomedix and ENTADFI, reported sharply lower revenue and continuing losses for the quarter ended June 30, 2025. Revenue was $106,494 in the quarter (down from $704,848 a year earlier) and $208,124 for the six months (versus $1,405,281). The company recorded a quarterly net loss of $(2,372,442) and a six-month net loss of $(10,918,327), which included significant goodwill impairment charges (approximately $594,000 for the quarter and $11,512,000 for six months).
Balance-sheet and liquidity pressures are prominent: total assets fell to $19.12 million, goodwill to $18.12 million, cash was $283,515 at June 30, 2025 (approximately $0.2 million as of August 13, 2025), and the company used ~$3.41 million of operating cash in the first half of 2025. Management discloses a working capital deficit of ~$11.8 million and substantial doubt about the company’s ability to continue as a going concern without additional financing or use of the ELOC (approximately $17.0 million available as of August 13, 2025). Near-term debt obligations include Veru notes with principal payments due in August 2025.